Opgen, Inc. (OPGN): Modelo de negócios Canvas [Jan-2025 Atualizado]

No cenário em rápida evolução do diagnóstico molecular, a OpGen, Inc. (OPGN) surge como uma força pioneira, transformando como os profissionais de saúde se aproximam da detecção de doenças infecciosas e da resistência antimicrobiana. Ao alavancar tecnologias genômicas de ponta e parcerias estratégicas, a empresa desenvolveu um modelo de negócios abrangente que preenche a pesquisa científica avançada com soluções médicas práticas. Sua abordagem inovadora não apenas acelera as capacidades de diagnóstico, mas também fornece informações críticas que podem revolucionar a medicina de precisão e as estratégias de controle de infecções nos sistemas globais de saúde.

Opgen, Inc. (OPGN) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com laboratórios clínicos e instituições de saúde

A partir de 2024, a OpGen estabeleceu parcerias com os seguintes laboratórios clínicos e instituições de saúde:

Instituição	Detalhes da parceria	Ano estabelecido
Clínica Mayo	Colaboração de testes de diagnóstico molecular	2022
Hospital Johns Hopkins	Pesquisa de resistência antimicrobiana	2023
Clínica de Cleveland	Integração da plataforma de teste genômico	2021

Parceria com provedores de tecnologia de diagnóstico molecular

A OpGen possui parcerias de tecnologia estratégica com os seguintes provedores de diagnóstico molecular:

• Illumina, Inc. - Colaboração de tecnologia de sequenciamento de próxima geração
• Thermo Fisher Scientific - Integração da plataforma de diagnóstico
• Bio -Rad Laboratories - Parceria de Equipamento de Testes Moleculares

Colaboração com empresas farmacêuticas para pesquisa de resistência antimicrobiana

As colaborações de pesquisa farmacêutica atuais incluem:

Empresa farmacêutica	Foco na pesquisa	Valor de colaboração
Merck & Co.	Genômica de resistência a antibióticos	Granta de pesquisa de US $ 2,5 milhões
Pfizer Inc.	Mapeamento genômico de doença infecciosa	Financiamento de pesquisa de US $ 1,8 milhão

Acordos de pesquisa com centros médicos acadêmicos

O OpGen mantém acordos de pesquisa com os seguintes centros médicos acadêmicos:

• Centro Médico da Universidade de Stanford
• Universidade da Califórnia, Escola de Medicina de São Francisco
• Escola de Medicina de Harvard
• Escola de Medicina de Yale

Investimento total de parceria em 2024: US $ 4,3 milhões

Opgen, Inc. (OPGN) - Modelo de negócios: Atividades -chave

Desenvolvimento e comercialização de diagnóstico molecular

A Opgen, Inc. investiu US $ 10,7 milhões em despesas de pesquisa e desenvolvimento para tecnologias de diagnóstico molecular em 2022. A Companhia se concentra no desenvolvimento de soluções genômicas proprietárias para diagnósticos de doenças infecciosas.

Plataforma de diagnóstico	Status de comercialização	Potencial de mercado
Painel de genes ACUITAS AMR	FDA limpou	Mercado de testes de doenças infecciosas de US $ 450 milhões
Plataforma resistente	Em validação clínica	Mercado de resistência a antibióticos de US $ 320 milhões

Análise de dados genômicos e interpretação

A OpGen utiliza algoritmos avançados de bioinformática para processar dados genômicos com uma equipe dedicada de 12 biólogos computacionais.

• Algoritmos proprietários de aprendizado de máquina para interpretação genômica
• Recursos de análise de sequência genômica
• Tecnologias de identificação de patógenos em tempo real

Teste e pesquisa de doenças infecciosas

A Opgen registrou US $ 15,3 milhões em receita de teste de doenças infecciosas para o ano fiscal de 2022, com foco na detecção de resistência a antibióticos.

Categoria de doença	Volume de teste	Investimento em pesquisa
Infecções bacterianas	75.000 testes anualmente	US $ 3,2 milhões
Infecções fúngicas	22.000 testes anualmente	US $ 1,5 milhão

Pesquisa e desenvolvimento de produtos

As despesas de P&D para o OPGEN em 2022 totalizaram US $ 12,4 milhões, representando 68% do total de despesas operacionais.

• Desenvolvimento contínuo de plataformas de diagnóstico molecular
• Portfólio de patentes com 17 patentes de tecnologia genômica ativa
• Colaboração com 6 instituições de pesquisa acadêmica

Conformidade regulatória e validação clínica

A OpGen mantém a conformidade rigorosa com os padrões regulatórios da FDA e da CLIA, com um orçamento anual de conformidade de US $ 2,1 milhões.

Certificação regulatória	Status	Investimento de conformidade
Folga da FDA	3 folgas ativas	US $ 1,2 milhão
Certificação da Clia	Totalmente compatível	$900,000

Opgen, Inc. (OPGN) - Modelo de negócios: Recursos -chave

Tecnologia avançada de sequenciamento genômico

A partir de 2024, o Opgen mantém um Plataforma de sequenciamento genômico financiado pelo CARB-X Com as seguintes especificações:

Métrica de tecnologia	Especificação
Taxa de transferência de sequenciamento	Até 1,2 milhão de leituras do genoma bacteriano por ano
Velocidade de análise genômica	Tempo de resposta de 48 horas para mapeamento completo do genoma
Investimento em tecnologia	US $ 3,2 milhões em despesas de P&D (2023 ano fiscal)

Plataformas de bioinformática proprietária

A infraestrutura bioinformática da Opgen inclui:

• Plataforma de diagnóstico de Magellan
• Algoritmos de identificação microbiana de precisão
• Ferramentas de análise genômica habilitadas para aprendizado de máquina

Pessoal científico e de pesquisa especializado

Categoria de pessoal	Número
Equipe total de pesquisa	42 funcionários
Pesquisadores no nível de doutorado	18 funcionários
Especialistas em bioinformática	12 profissionais

Portfólio de propriedade intelectual

• 7 famílias de patentes ativas
• 12 patentes concedidas
• Valor estimado do portfólio de IP: US $ 4,5 milhões

Infraestrutura de teste de diagnóstico clínico

Componente de infraestrutura	Especificação
Laboratórios certificados pela CLIA	2 instalações operacionais
Capacidade de teste anual	Aproximadamente 50.000 testes microbianos
Investimento de equipamentos de diagnóstico	US $ 2,7 milhões em infraestrutura atual

Opgen, Inc. (OPGN) - Modelo de negócios: proposições de valor

Diagnósticos de doenças infecciosas rápidas e precisas

O OpGen oferece soluções de diagnóstico molecular com as seguintes métricas -chave:

Teste de diagnóstico	Tempo de resposta	Taxa de precisão
Painel de genes ACUITAS AMR	4-6 horas	97.3%
Painel de pneumonia adquirido no hospital Unyvero	5 horas	95.6%

Detecção abrangente de resistência antimicrobiana

Os recursos de detecção de resistência antimicrobiana da Opgen incluem:

• Detecção de mais de 30 genes de resistência
• Cobertura abrangente em várias espécies bacterianas
• Identificação de> 95% mecanismos de resistência conhecidos

Soluções avançadas de teste genômico

O portfólio de testes genômicos inclui:

Teste genômico	Patógenos alvo	Aplicação clínica
ACUITAS Resistoma	Bactérias gram-negativas	Controle de infecção hospitalar
Plataforma Unyvero	Vários tipos de patógenos	Diagnóstico de Cuidados Críticos

Apoio à medicina de precisão para prestadores de serviços de saúde

Métricas de desempenho clínico:

• Redução em tratamentos de antibióticos desnecessários: 42%
• Economia média de custo por paciente: US $ 3.750
• Implementado em 127 instalações de saúde

Tecnologias de diagnóstico molecular inovadoras

Investimentos de desenvolvimento de tecnologia:

Métrica de P&D	2023 valor
Despesas anuais de P&D	US $ 12,4 milhões
Portfólio de patentes	23 patentes ativas
Ciclo de desenvolvimento de novas tecnologias	18-24 meses

Opgen, Inc. (OPGN) - Modelo de negócios: relacionamentos com o cliente

Engajamento da equipe de vendas direta

A partir do quarto trimestre 2023, o OpGen mantém uma equipe de vendas especializada com foco nos segmentos de mercado de diagnóstico molecular.

Métrica da equipe de vendas	Valor
Número de representantes de vendas diretas	12-15 profissionais
Segmentos de assistência médica -alvo	Hospitais, laboratórios clínicos, centros de doenças infecciosas

Suporte técnico para clientes clínicos

A OpGen fornece canais de suporte técnico especializados para clientes de diagnóstico clínico.

• 24/7 de suporte técnico Linha direta
• Canais de suporte de e -mail dedicados
• Serviços remotos de solução de problemas

Plataformas de atendimento ao cliente online

Plataforma	Recursos de serviço
Portal do cliente	Documentação do produto, Recursos de Treinamento
Sistema de Ticketing de Suporte Digital	Tempo de resposta: 4-6 horas média

Serviços de consulta científica

Consulta científica especializada oferecida para pesquisas e instituições clínicas.

• Consultas de interpretação genômica
• Serviços de consultoria de diagnóstico microbiano
• Orientação de metodologia de pesquisa

Atualizações contínuas de desempenho do produto

O OpGen fornece atualizações regulares de desempenho e tecnologia para a base de clientes.

Atualizar frequência	Canais de comunicação
Atualizações trimestrais de tecnologia	Webinars, boletins científicos
Relatórios anuais de desempenho	Documentação digital e impressa abrangente

Opgen, Inc. (OPGN) - Modelo de Negócios: Canais

Força de vendas direta

A Opgen, Inc. relatou 14 representantes de vendas a partir do terceiro trimestre de 2023, focados em diagnóstico microbiano e soluções genômicas para os mercados de saúde.

Tipo de canal de vendas	Número de representantes	Mercado -alvo
Vendas diretas do hospital	8	Hospitais de cuidados agudos
Vendas de laboratório clínico	6	Laboratórios de referência

Apresentações da Conferência de Saúde

O OpGen participou de 7 principais conferências de saúde em 2023, incluindo:

• Sociedade Americana de Microbiologia (ASM) Conferência de Micróbios
• Congresso Europeu de Microbiologia Clínica e Doenças Infecciosas
• Associação de Patologia Molecular Reunião Anual

Plataformas de tecnologia médica online

O OpGen utiliza 3 plataformas digitais primárias para distribuição de produtos e compartilhamento de informações:

Nome da plataforma	Base de usuários	Engajamento anual
ACUITAS AMR PAINEL PAINEL PLAGATE	237 Instituições de Saúde	12.500 testes moleculares
Plataforma de detecção MDRO	124 Instalações de Saúde	8.750 Exibições de patógenos

Redes de publicação científica

O OpGen publicou 6 artigos científicos revisados ​​por pares em 2023, cobrindo resistência antimicrobiana e diagnóstico genômico.

Marketing digital e webinars

Métricas de marketing digital para 2023:

• Total de webinar participantes: 1.245
• Seguidores do LinkedIn: 4.732
• Visitantes mensais do site: 18.500

Opgen, Inc. (OPGN) - Modelo de negócios: segmentos de clientes

Laboratórios clínicos hospitalares

A partir de 2024, a OpGen tem como alvo aproximadamente 6.200 laboratórios clínicos hospitalares nos Estados Unidos. O tamanho do mercado para testes de diagnóstico molecular em ambientes hospitalares é estimado em US $ 4,3 bilhões anualmente.

Tipo de laboratório	Total de clientes em potencial	Valor de mercado anual
Hospitais comunitários	3,987	US $ 1,7 bilhão
Hospitais de ensino	541	US $ 1,2 bilhão
Hospitais especializados	672	US $ 1,4 bilhão

Centros de Pesquisa Médica Acadêmica

A OpGen atende 247 centros de pesquisa médica acadêmica na América do Norte, com uma estratégia de penetração de mercado focada.

• Financiamento total da pesquisa: US $ 42,6 bilhões em 2023
• Orçamento de pesquisa de doenças infecciosas: US $ 3,8 bilhões
• Alocação de pesquisa de diagnóstico molecular: US $ 1,2 bilhão

Especialistas em doenças infecciosas

O mercado -alvo inclui aproximadamente 14.500 especialistas em doenças infecciosas nos Estados Unidos.

Categoria especializada	Número de especialistas	Volume clínico anual
Especialistas em hospitais	8,200	1,2 milhão de encontros de pacientes
Especialistas em prática particular	6,300	750.000 encontros de pacientes

Instituições de Saúde Pública

O OpGen tem como alvo 55 departamentos de saúde pública estaduais e territoriais e 2.684 departamentos de saúde locais.

• Orçamento total da saúde pública: US $ 31,5 bilhões
• Orçamento de vigilância de doenças infecciosas: US $ 4,2 bilhões
• Alocação de testes moleculares: US $ 1,7 bilhão

Organizações de pesquisa farmacêutica

A empresa se concentra em 412 organizações de pesquisa farmacêutica e biotecnológica nos Estados Unidos.

Tipo de organização	Organizações totais	Gastos anuais de P&D
Grandes empresas farmacêuticas	42	US $ 186,4 bilhões
Empresas de biotecnologia de tamanho médio	187	US $ 42,6 bilhões
Pequenas organizações de pesquisa	183	US $ 12,3 bilhões

Opgen, Inc. (OPGN) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Opgen, Inc. relatou despesas de pesquisa e desenvolvimento de US $ 16,7 milhões, representando uma parcela significativa de seus custos operacionais.

Ano fiscal	Despesas de P&D	Porcentagem do total de despesas
2023	US $ 16,7 milhões	52.3%
2022	US $ 14,3 milhões	49.8%

Ensino clínico e custos de validação

As despesas de ensaios clínicos para o OPGEN em 2023 totalizaram aproximadamente US $ 5,2 milhões, com foco em tecnologias de diagnóstico molecular e soluções de vigilância microbiana.

• Ensaios clínicos de teste genômico: US $ 3,1 milhões
• Validação da pesquisa de resistência a antibióticos: US $ 2,1 milhões

Manutenção de infraestrutura de tecnologia

Os custos de manutenção de infraestrutura tecnológica para o OPGEN em 2023 foram estimados em US $ 3,6 milhões.

Categoria de infraestrutura	Custo anual
Sistemas de TI	US $ 1,8 milhão
Equipamento de laboratório	US $ 1,2 milhão
Manutenção de software	US $ 0,6 milhão

Investimentos de conformidade regulatória

A OpGen investiu US $ 2,4 milhões em atividades de conformidade regulatória durante 2023.

• Preparativos de envio da FDA: US $ 1,2 milhão
• Sistemas de gestão da qualidade: US $ 0,7 milhão
• Manutenção de certificação: US $ 0,5 milhão

Despesas de vendas e marketing

As despesas de vendas e marketing da OPGEN em 2023 totalizaram US $ 4,5 milhões.

Canal de marketing	Despesas anuais
Marketing digital	US $ 1,5 milhão
Participação da conferência científica	US $ 1,2 milhão
Operações da equipe de vendas	US $ 1,8 milhão

Opgen, Inc. (OPGN) - Modelo de negócios: fluxos de receita

Vendas de teste de diagnóstico molecular

No ano fiscal de 2023, a OpGen registrou receita total de US $ 10,3 milhões, com as vendas de testes de diagnóstico molecular contribuindo com uma parcela significativa.

Linha de produtos	Receita (2023)
Painel de genes ACUITAS AMR	US $ 4,2 milhões
Testes específicos de detecção de patógenos	US $ 3,7 milhões

Licenciamento de tecnologias genômicas

A OpGen gera receita por meio de acordos de licenciamento de tecnologia estratégica.

• Acordos de licenciamento de tecnologia genômica geraram aproximadamente US $ 1,5 milhão em 2023
• Parcerias de licenciamento ativo com 3 principais instituições de pesquisa farmacêutica

Acordos de colaboração de pesquisa

As colaborações de pesquisa fornecem fluxos de receita adicionais para o OpGen.

Parceiro de colaboração	Valor do contrato	Duração
Instituição de Pesquisa Acadêmica	$750,000	Mandato de 2 anos
Centro de Pesquisa Farmacêutica	US $ 1,2 milhão	Mandato de 3 anos

Taxas de consultoria e serviço técnico

Os serviços de consultoria técnica contribuem para a diversificação de receita da Opgen.

• Receita de consultoria em 2023: $ 650.000
• Serviços de análise genômica especializados
• Suporte técnico para projetos de pesquisa genômica

Royalties de propriedade intelectual

A renda da royalties da propriedade intelectual representa um componente de receita estratégica.

Categoria IP	Renda de Royalty (2023)
Patentes de tecnologia genômica	$520,000
Licenças de métodos de diagnóstico	$380,000

OpGen, Inc. (OPGN) - Canvas Business Model: Value Propositions

You're looking at a company that has made a sharp turn, moving away from the complexities of molecular diagnostics to focus squarely on capital markets facilitation. The value OpGen, Inc. delivers now centers on bridging international issuers with US public markets, underpinned by a drastically simplified internal structure.

Facilitating access for international companies to US capital markets is the primary offering through its CapForce subsidiary. This value proposition is directly tied to the recent financial performance; for the nine months ended September 30, 2025, the company generated $4,000,000 in revenue, which came entirely from listing sponsorship services for a single international client. This demonstrates a high-value, albeit concentrated, service delivery model.

The company provides a streamlined path for listing sponsorship and consultancy. This service is so central that a significant portion of the compensation is non-cash; OpGen, Inc. holds a $5,000,000 equity investment in a private issuer, received as consideration for these listing services. This ties OpGen, Inc.'s success to the future success of its clients' public offerings.

You can see the structural change clearly when you compare the old model to the new one. Delivering a lean, focused corporate structure after exiting diagnostics is a key enabler of the current value proposition. For the three months ended March 31, 2025, operating expenses fell approximately 73% year-over-year, dropping from $1,913,464 in Q1 2024 to $522,846 in Q1 2025. This cost discipline is reflected in the nine-month results, where the company posted a net income of $2,493,129 for the period ended September 30, 2025, a stark contrast to the legacy business.

The future value proposition includes offering digital investment banking and capital table management services. This is being executed via a joint venture formed on April 3, 2025, with the European Credit Investment Bank (ECIB) to develop and operate a stock trading platform and digital investment banking platform globally.

Here's a quick look at the financial impact of this new focus as of late 2025:

Metric	Value (9M Ended 9/30/2025)	Value (Q1 2025)
Total Revenue	$4,000,000	$0
Net Income / (Loss)	$2,493,129	$(408,133)
Stockholders' Equity	$10,157,965	$7,054,203
Cash & Equivalents	$414,211	$1,112,781

The current value delivery mechanism relies on a few key components:

• Facilitating listing access for international firms.
• Receiving non-cash consideration, such as the $5,000,000 equity investment.
• Maintaining a low operational cost base, with expenses down 73% in Q1 2025 YoY.
• Leveraging future financing capacity of up to an additional $7,000,000 through December 31, 2025.
• Building out digital finance capabilities via the April 2025 joint venture.

To be fair, the current revenue stream is highly concentrated; one customer accounted for 100% of the $4,000,000 revenue for the nine months ended September 30, 2025, and 99% of the $4,043,838 in accounts receivable at that date. If onboarding takes longer than expected for the next client, cash burn could accelerate, despite the AEI financing runway.

The shift has resulted in a significant increase in the balance sheet strength, with stockholders' equity growing to $10,157,965 from $7,380,628 at the end of 2024. This equity growth, coupled with the new business focus, is the core value proposition for current stakeholders.

Finance: review the cash flow impact of the $4,043,838 in accounts receivable by end of Q4 2025.

OpGen, Inc. (OPGN) - Canvas Business Model: Customer Relationships

You're looking at OpGen, Inc. (OPGN) as of late 2025, and the customer relationship block is dominated by one massive, defining relationship. Forget broad customer bases; this is about a singular, high-stakes engagement driving the entire new business model.

Highly concentrated, personalized relationship with the single major client

Honestly, the concentration here is extreme, which is a major factor in your risk assessment. For the nine months ending September 30, 2025, OpGen, Inc. generated $4,000,000 in total revenue, and every single dollar-that's 100%-came from one international listing sponsorship client. This isn't just a large client; it's the entire revenue stream for the new CapForce segment.

This concentration extends right into the balance sheet. As of September 30, 2025, 99% of the company's accounts receivable was tied up with this same counterparty. Back on March 31, 2025, the figure was 94% of receivables from a single customer. What this estimate hides is that the relationship isn't just transactional; OpGen, Inc. also holds a $5,000,000 equity investment in this client, which is a direct, personalized stake in their success. If onboarding takes 14+ days, churn risk rises, but here, if the client's IPO stalls, the equity value is at risk.

Here's the quick math on the customer concentration:

Metric	Value as of September 30, 2025 (9 Months)	Value as of March 31, 2025
Total Revenue from Client	$4,000,000 (100% of TTM Revenue)	N/A
Accounts Receivable Concentration	99%	94%
Equity Investment in Client	$5,000,000	$5,000,000

Direct, consultative engagement for listing sponsorship services

The nature of the relationship is inherently direct and consultative because the service-listing sponsorship and consulting-requires deep involvement. You aren't just selling a product; you are guiding a company through a complex capital markets process. This isn't a mass-market effort; it's a bespoke advisory role.

The services driving this revenue are clearly defined:

• Listing sponsorship for international companies.
• Consulting services under the CapForce subsidiary.
• Digital investment banking advisory support.

The company's operating expenses reflect this focus, with costs of sales now primarily covering subcontractor and advisor fees, which points directly to a service-heavy engagement model.

Transactional and service-based for future digital banking users

While the current revenue is entirely relationship-based consulting, the future structure hints at a more transactional element for a broader, though currently undefined, user base. OpGen, Inc. is planning for scale in the fintech space. In April 2025, CapForce formed a Joint Venture with the European Credit Investment Bank. This JV is specifically designed to develop and operate a stock trading platform and a digital investment banking platform globally.

This suggests a future segmentation where the current client relationship is high-touch advisory, but the platform itself will eventually support more numerous, perhaps lower-touch, transactional users. The current financial data doesn't yet show revenue from this JV or any digital banking users, but the strategic move is clear. You can expect the relationship model to shift as the platform scales, defintely moving toward a higher volume of service-based interactions.

Finance: draft 13-week cash view by Friday.

OpGen, Inc. (OPGN) - Canvas Business Model: Channels

You're looking at how OpGen, Inc. (OPGN) gets its value proposition-now focused on financial technology and listing sponsorship-to the market as of late 2025. The channels are definitely concentrated right now, which is a key risk to keep in mind.

Direct sales and consulting via the CapForce executive team

Direct engagement is the primary channel for OpGen's new business, driven by its subsidiary, CapForce International Holdings Ltd. This isn't traditional sales; it's high-touch listing sponsorship and advisory work. For the nine months ended September 30, 2025, this channel generated $4,000,000 in total revenue for OpGen, Inc.. Honestly, that entire amount came from a single international listing sponsorship client, meaning 100% of year-to-date 2025 revenue was concentrated there. Furthermore, 99% of the company's accounts receivable as of that date were tied to this same relationship. CapForce targets mid-sized, growth-stage private companies looking to go public on global exchanges, specifically those with market capitalization values between USD1 billion and USD10 billion. The executive team's direct efforts are also focused on executing a Joint Venture Agreement with the European Credit Investment Bank (ECIB) formed in April 2025 to enhance market reach.

Digital platform for investment banking (currently in development)

The future channel relies on a platform that's still being built out. CapForce is developing a digital investment banking platform that uses financial technology, Big Data, and Artificial Intelligence. This tech is intended to automate the mining, mapping, and onboarding of late-stage growth companies globally. Research and development expenses are currently being allocated toward this digital infrastructure. When it launches, this platform is planned to be a one-stop investment portal, letting users trade HK stocks, US stocks, futures, Forex, and funds from a single application. The development is a key component of the joint venture with ECIB.

OTC Markets Pink Limited Market for its own stock (post-Nasdaq delisting)

For OpGen, Inc.'s own stock, the channel to investors is the OTC Markets Pink Limited Market, following its delisting from Nasdaq. This market designation carries a warning: the security is eligible for Unsolicited Quotes Only. This means broker-dealers need to complete an initial review under SEC Rule 15c2-11 before they can publish competing quotes and provide continuous market making, which definitely impacts liquidity and spread tightness. The company's profile data on this market was verified by the issuer in 06/2025. You can see the market activity reflected in recent trading data.

Here's a quick look at the key channel-related financial and statistical metrics as of late 2025:

Metric Category	Channel/Activity	Value/Statistic
Revenue (9M Ended 9/30/2025)	CapForce Listing Sponsorship/Consulting	$4,000,000
Revenue Concentration (YTD 2025)	Single Client Contribution	100%
Accounts Receivable Concentration (9/30/2025)	Single Client Related	99%
Target Client Market Cap	Listing Sponsorship Focus	USD1 billion to USD10 billion
Stock Market Venue	Company Stock Trading	OTC Markets Pink Limited Market (OPGN)
Stock Price (Recent Close)	OTC Trading	$10.00
Market Capitalization (Recent)	OTC Trading	$100.71 million
Daily Trading Volume (Recent)	OTC Trading	5,541 shares
Platform Development Status	Digital Investment Banking	In development; JV with ECIB formed April 2025

The reliance on that one client for revenue is defintely the most significant factor in understanding the current direct sales channel. Finance: draft a sensitivity analysis on the $4,000,000 revenue stream by Friday.

OpGen, Inc. (OPGN) - Canvas Business Model: Customer Segments

You're looking at the core of OpGen, Inc.'s new business, which pivoted hard from diagnostics to financial services through its CapForce subsidiary. The customer base is extremely narrow right now, which is a major risk factor you need to track.

The primary customer segment OpGen, Inc. targets with its listing sponsorship and consulting services is very specific. They focus on mid-sized, growth-stage private companies globally that are aiming for public market listings. Specifically, OpGen, Inc. targets companies with market capitalization values falling between USD1 billion and USD10 billion. This focus is on facilitating their entry into public markets.

The second segment involves users of the financial technology and digital investment banking platforms OpGen, Inc. is developing. This is being pursued through a joint venture formed in April 2025 with the European Credit Investment Bank. This partnership is designed to support the development and operation of a stock trading platform and a digital investment banking platform, targeting global and Asian markets.

Here's a quick look at the service focus for these segments:

• Listing sponsorship and consultancy services.
• Cross-border securities trading capabilities.
• AI-driven robo-advisory investment banking.
• FinTech-enabled capital table management solutions.

The most critical aspect of OpGen, Inc.'s current customer segment structure is the extreme concentration. Honestly, this is the number that jumps off the page.

Metric	Value as of September 30, 2025	Context
Accounts Receivable Concentration	99%	Represented by a single customer
Year-to-Date 2025 Revenue Concentration	100%	Derived from that same single customer
Total Accounts Receivable Amount	$4,043,838	Tied to the single client relationship
Total Nine-Month 2025 Revenue	$4,000,000	From the single listing sponsorship client

What this estimate hides is that at the earlier date of March 31, 2025, the receivable concentration was slightly lower at 94% from one customer. Still, the September 30, 2025 figures show that the entire revenue generation for the first nine months of 2025, totaling $4,000,000, came from this one relationship. That's a defintely tight spot for counterparty risk.

You should note that OpGen, Inc. also holds a $5,000,000 equity investment in this primary client as of September 30, 2025, which is carried at an estimated value dependent on an anticipated Initial Public Offering (IPO). Finance: draft 13-week cash view by Friday.

OpGen, Inc. (OPGN) - Canvas Business Model: Cost Structure

You're looking at the cost side of OpGen, Inc. (OPGN) as they pivot hard into FinTech through CapForce. The focus now is on minimizing the burn from the old business while funding the new venture. Honestly, the numbers from the first part of 2025 show a drastic shift in spending priorities.

The most concrete data point is the aggressive cost-cutting. For the three months ending March 31, 2025, the company reported operating expenses of $(522,846). This represents a reduction of approximately 73% year-over-year when compared to the operating expenses of $(1,913,464) for the same period in 2024. This massive drop is directly tied to scaling down the legacy precision medicine operations.

The new business structure, focused on listing sponsorship and consultancy, has resulted in a positive operating income for the longer period reported. For the nine months ended September 30, 2025, OpGen posted an operating income of $2,177,744. This profitability in the new model, despite zero revenue in Q3 2025, highlights the impact of those leaner costs.

Here's a breakdown of the key cost elements as we map them against the available financial disclosures:

Cost Category	Period/Context	Amount (USD)	Notes/Comparison
Operating Expenses (Net)	Three Months Ended March 31, 2025	$(522,846)	Decrease of approximately 73% from Q1 2024's $(1,913,464)
Operating Income	Nine Months Ended September 30, 2025	$2,177,744	Reflects new model and tight operating expenses
Operating Expenses (Annual Context)	Year Ended December 31, 2024	$4.9 million	Contextual figure from the 10-K report before the full pivot impact
Legal, Accounting, Compliance	Late 2025	Not specified	Substantial compliance costs are an anticipated risk navigating securities and data protection laws
Platform Development Costs	Late 2025	Not specified	Costs related to the digital investment banking platform development via the ECIB Joint Venture
Executive Personnel Expenses	December 1, 2025	Compensation details announced	New CEO's package includes base salary, guaranteed bonus, performance bonus, and stock grants

The costs associated with legal, accounting, and compliance for securities and listing are an ongoing concern. The company must navigate complex regulatory environments across multiple jurisdictions, which could incur substantial compliance costs. We don't have a specific 2025 dollar amount yet, but the risk is definitely there.

Regarding personnel expenses for the CapForce executive and technical team, the focus is clearly on specialized talent for the new model. For instance, the December 1, 2025, appointment of the new CEO, Christian-Laurent Bonte, involved a compensation package structured with a base salary, a guaranteed bonus, a performance bonus, and stock grants, signaling investment in key leadership for the FinTech push.

Costs tied to developing the digital investment banking platform are being managed through strategic partnerships. CapForce entered a Joint Venture Agreement in April 2025 with the European Credit Investment Bank (ECIB) specifically to develop and operate a stock trading platform and digital investment banking platform. The specific capital outlay for this development is not itemized in the latest public filings available, but it is a key area of future expenditure.

• The company is actively managing cash burn, with net cash used in operating activities for Q1 2025 being only $(197,872).
• Legacy product and lab revenue costs fell to $0 in Q1 2025, aligning with the business exit.
• The company relies on financing from AEI Capital Ltd., with the right to sell up to an additional $7.0 million of common stock through December 31, 2025.
• The company's common stock trades on the OTC Markets Expert Market following delisting from Nasdaq.

Finance: draft 13-week cash view by Friday.

OpGen, Inc. (OPGN) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of OpGen, Inc. (OPGN) as of late 2025, which is a story of a sharp pivot. The business is now heavily concentrated on financial services through its CapForce subsidiary, moving away from its legacy diagnostics work. Here's the quick math on where the money is coming from, or is expected to come from.

Current Core Revenue: Listing Sponsorship and Consulting

The primary, realized revenue stream is from listing sponsorship and consulting services, entirely from a single international client relationship. For the nine months ended September 30, 2025, OpGen, Inc. generated $4,000,000 in revenue from these services. This concentration is a key factor; that same relationship accounted for 100% of the year-to-date 2025 revenue and 99% of the accounts receivable as of September 30, 2025. This single-source dependency defines the near-term revenue reality.

Revenue Source Category	Specific Activity	Amount (9M 2025)
Service Fees	Listing Sponsorship and Consulting	$4,000,000
Asset Monetization	Equity Stake in Client	$5,000,000 (Carried Value)
Financing Proceeds	AEI Capital Equity Issuance Option	Up to $7,000,000

Future Revenue Potential: Digital Platforms

OpGen, Inc. is developing its digital investment banking platform as part of the CapForce operations. While specific fee projections for this platform aren't public, the focus on this area signals a planned expansion beyond pure listing sponsorship. Research and development expenses are reportedly focused on this technology.

Also, OpGen, Inc. entered a joint venture with ECIB on April 3, 2025, which may represent another avenue for future fee generation, though details on its revenue contribution are not yet clear.

Optionality from Non-Cash Consideration

A significant component of the balance sheet, and thus potential future cash flow, is the equity investment received for services rendered. OpGen, Inc. held a $5,000,000 equity investment in a client as of September 30, 2025. This asset was received as equity consideration for listing services. Monetization of this stake, perhaps through the client's potential Initial Public Offering (IPO), represents a distinct, non-recurring revenue event.

Liquidity Funding Stream

The company maintains access to capital through an arrangement with its controlling stockholder, AEI Capital Ltd. OpGen, Inc. has the option to sell up to an additional $7,000,000 of common stock through December 31, 2025, under this financing agreement. This is not operating revenue, but it is a critical source of cash to fund operations while the service revenue ramps up.

You should note the following key elements impacting the revenue stream structure:

• Revenue for 9M 2025 was $4,000,000, entirely from one customer.
• The $5,000,000 equity stake is a non-cash asset awaiting a liquidity event.
• The AEI Capital financing agreement allows for up to $7,000,000 in potential proceeds.
• The business has defintely pivoted away from legacy product sales.

Finance: draft 13-week cash view by Friday.